Get it on Google Play

Soligenix receives FDA orphan drug designation for Behçet's disease

August 18, 2025 7:30 AM EDT Send to a Friend
Soligenix Inc. (NASDAQ: SNGX) announced that the U.S. Food and Drug Administration has granted orphan drug designation to dusquetide, the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login